Patent number: 6632828
Abstract: Compounds of the formula I
or a pharmaceutically acceptable salt, solvate or N-oxide thereof, wherein
X is ═CH— or ═N—;
Y is H, halogen, trihaloalkyl, alkyl, alkenyl, cycloalkyl, cycloalkyl, SH, —S-alkyl, or —CN.
R is alkyl, —CF3, cycloalkyl, heterocycloalkyl, heterocycloalkyl-alkyl, heteroarylalky or adamantyl, or optionally substituted phenyl, phenoxyalkyl, phenylthioalkyl, pyridyl, thienyl, thiazolyl, pyrazinyl, 1,2,5,6-tetrahydropyridine or
wherein R10 and R11 are hydrogen, alkyl or together form a cycloalkyl, are disclosed, as well as pharmaceutical compositions and methods of using said compounds in the treatment of eating disorders and diabetes.
Type:
Grant
Filed:
July 23, 2002
Date of Patent:
October 14, 2003
Assignee:
Schering Corporation
Inventors:
Andrew W. Stamford, Craig D. Boyle, Ying Huang
Patent number: 6514969
Abstract: Compounds of general formula (I)
wherein:
A is —CH2—, —CH2—CH2—, —CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—, —CH2—CO—, —CH2—CH2—CO—, or —CH═CH—CO—;
Het is piperidinyl, piperazinyl, or dihydrobenzimidazolonyl;
R1 is hydrogen or halogen;
R2 is hydrogen, C1-C4-alkyl, CF3, or a phenyl group optionally substituted by halogen, C1-C4-alkyl, or C1-C4-alkyloxy; and
R3 is hydrogen, C1-C4-alkyl, HO—C1-C4-alkyl, or C2-C4-alkenyl; or a group selected from phenyl, benzyl, and phenylethyl, each optionally substituted by halogen, CF3, C1-C4-alkyl, or C1-C4-alkyloxy; or a heterocycle selected from among morpholine, piperidine, piperazine, and dihydrobenzimidazolone, the heterocycle either linked directly or via a C1-C4-alkylene bridge,
or an optical isomer, enantiomer, tautomer, free base, or pharmacologically acceptable acid addition salt thereof; methods of
Type:
Grant
Filed:
July 24, 2001
Date of Patent:
February 4, 2003
Assignee:
Boehringer Ingelheim Pharma KG
Inventors:
Hans Briem, Klaus Mendla, Helmut Michael Romig, Katja Fechteler, Klaus Fuchs
© 2024 Justia
